

List of Abbreviations:

SGLT2: sodium-glucose cotransporter 2

HF: Heart Failure

HHF: Hospitalization for heart failure

CV: Cardiovascular

RCTs: Randomized control studies

GDMT: guideline-directed medical therapy

RAAS: Renin-Angiotensin-Aldosterone-System

ARB: Angiotensin receptor blocker

ACEi: Angiotensin-converting enzyme inhibitors

ARNI: Angiotensin receptor/Neprilysin inhibitor

MRA: Mineralocorticoid receptor antagonists

RR: Risk Ratio

OR: Odds Ratio

CI: Confidence interval

NYHA: New York heart association,


LVEF: left ventricular ejection fraction



T2DM: type 2 diabetes mellites

HTN: hypertension

CAD: coronary artery disease

AF: atrial fibrillation





Study or Subgroup	SGLT2 inhibitor Events	SGLT2 inhibitor Total	Placebo Events	Placebo Total	Weight	Odds ratio M-H, Random, 95% CI	Odds ratio M-H, Random, 95% CI
✓ DAPA-HF trial	227	2373	273	2371	21.9%	0.81 [0.67, 0.98]	
✓ DECLARE-TIMI 58 trial	79	980	85	1007	7.4%	0.95 [0.69, 1.31]	
✓ DELIVER Trial	231	3131	261	3132	22.3%	0.88 [0.73, 1.05]	
✓ EMPA-REG OUTCOME trial	38	462	27	244	2.8%	0.72 [0.43, 1.21]	
✓ EMPEROR-Preserved trial	219	2997	244	2991	21.0%	0.89 [0.73, 1.07]	
✓ EMPEROR-Reduced trial	187	1863	202	1867	17.2%	0.92 [0.75, 1.13]	
✗ SOLOIST-WHF trial	51	608	58	614	0.0%	0.88 [0.59, 1.30]	
✓ VERTIS-CV trial	116	1286	64	672	7.4%	0.94 [0.68, 1.30]	
Total (HKSJ^a)		13092		12284	100.0%	0.88 [0.83, 0.93]	
Total events:	1097		1156				
Test for overall effect: T = 5.35, df = 6 (P = 0.002)							
Test for subgroup differences: Not applicable							
Heterogeneity: Tau ² (DL ^b) = 0.00; Chi ² = 1.84, df = 6 (P = 0.93); I ² = 0%							
Footnotes							
^a CI calculated by Hartung-Knapp-Sidik-Jonkman method.							
^b Tau ² calculated by DerSimonian and Laird method.							

0.1 0.2 0.5 1 2 5 10
SGLT2 inhibitor Placebo

Supplementary Figure 5: Statistical analysis and forest plot of cardiovascular deaths after sensitivity analysis.

